A San Francisco-based digital health company has crossed a landmark regulatory threshold in fertility medicine. Alife Health announced on May 28, 2026, that its product Embryo Predict has received clearance from the U.S. Food and Drug Administration, marking a significant step forward in AI-powered embryo assessment during in vitro fertilization. The tool is designed to give fertility specialists a data-driven, adjunctive layer of insight when making one of the most consequential decisions in the IVF process: which embryo to select for transfer.

IVF remains one of the most emotionally and financially demanding medical journeys a person can undergo. On average, patients in the U.S. go through three cycles before achieving a successful pregnancy. A core challenge has long been the selection of the right embryo a decision that, despite the expertise of seasoned clinicians, carries a surprisingly high degree of variability. Published research found a 34.6% disagreement rate among fertility specialists selecting the top embryo for transfer, rising to 44% when patients had three or more embryos to choose from.

That inconsistency underscores the need for standardized, evidence-backed tools. Embryo Predict addresses this gap directly. The system analyzes images of each embryo using artificial intelligence, drawing on patterns learned from thousands of embryos and their outcomes across clinics, geographies, and patient profiles worldwide. It integrates with microscopes and imaging systems already in use in fertility labs, with no new hardware required. Indicated for Day 5, 6, and 7 blastocyst-stage embryos deemed suitable for transfer, the device provides adjunctive information when multiple embryos are candidates for transfer or freezing based on standard morphological assessment.

The FDA clearance was backed by a prospective, randomized, multi-center clinical trial conducted at seven leading centers across the United States, enrolling 440 patients and evaluating AI-assisted embryo selection against standard evaluation alone. Melissa Teran, CEO and co-founder of Alife Health, placed the milestone in the context of the company's six-year journey: "Six years ago, we set out to put IVF's wealth of clinical data to work in a way the field had never seen before. Today, that work is validated. This clearance reflects years of rigorous clinical research and the trust of the clinicians and institutions who partnered with us. For the first time, the collective insight from thousands of embryos and outcomes around the world is available to every embryologist, at every transfer decision." Alison Bartolucci, Ph.D., HCLD, Chief Scientific Officer at First Fertility, echoed the significance of the development: "As the field of reproductive medicine advances, we have a responsibility to bring the most rigorous, evidence-based tools into our labs. Alife's Embryo Predict does exactly that. It layers AI-driven insight onto the clinical expertise already in the room, giving embryologists adjunctive AI information for one of the most consequential decisions in a patient's IVF journey."

Beyond the U.S. market, Embryo Predict already holds CE Mark under the European Union Medical Device Regulation and is now commercially available across the U.S., Europe, and the U.K. The combination of multi-jurisdictional regulatory approvals and a randomized clinical trial foundation positions Alife Health's AI-powered embryo assessment platform as one of the more rigorously validated entrants in the growing field of AI-assisted reproductive medicine.